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between the two groups. No Cardiac Death was observed. At 1-year angiographic
follow-up, no differences were showed in late lumen loss (small vessels 0.27±0.32mm
vs. large vessels 0.27±0.32mm, p=0.9852) and In-Scaffold Binary Restenosis (small
vessels 0/21 cases, 0.0% vs large vessels 2/36 cases, 5.6% p=0.5263).
Conclusion: The second generation BVS showed similar clinical and angiographic
outcomes at 1-year follow-up in small and large vessels.
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Background: Late serious adverse events associated with next generation drug-eluting
stents require further evaluation. At 4 years the ENDEAVOR IV study, comparing the
Endeavor zotarolimus-eluting stent (E-ZES) with the Taxus paclitaxel-eluting stent
(PES) indicated similar efficacy and significantly lower rates of clinically-driven
myocardial infarction (MI) and very late stent thrombosis (ST).
Methods: ENDEAVOR IV was a multicenter, randomized (1:1), single-blind,
controlled trial that enrolled 1548 patients undergoing percutaneous revascularization
for a single de novo native coronary lesion. The primary endpoint at 9 months was
target vessel failure (TVF; cardiac death, MI or clinically-driven target vessel
revascularization [TVR]), and safety endpoints included cardiac death, MI and ARC-
defined ST.
Results: Baseline clinical and angiographic characteristics were similar between
groups. Four-year clinical outcomes are in the Table.
TLR, target lesion revascularization; MACE, major adverse cardiac events
Conclusion: The 4 year results demonstrated comparable efficacy (TLR and TVR) for
E-ZES compared with PES and an improved safety profile with lower VLST and fewer
MIs. The “final” 5-year results of the ENDEAVOR IV study will be presented.
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Background: The 2009 American College of Cardiology (ACC) Appropriate Use
Criteria (AUC) for Coronary Revascularization categorized percutaneous coronary
interventions (PCI) as appropriate (A), uncertain (U), or inappropriate (I) according to
180 clinical scenarios. ACC released AUC hospital summary reports for PCI in May
2011.
Methods: We developed an algorithm based on the AUC scenarios and calculated
patient scores for the two Portland hospitals in our Providence Health & Services
(PH&S) healthcare system. After this successful pilot we applied this algorithm to 11
other PH&S facilities using PCI data from July 2009 through December 2010
(n=12,203, 66% acute, 34% non-acute). Results from our algorithm were compared to
the ACC results for 2010. We determined the primary reasons for inappropriate ratings
and unclassifiable cases.
Results: After excluding two facilities with fewer than 100 PCIs, non-scorable cases
(16%) were primarily due to no stress test performed (37%) or unavailable stress test
results (56%). For the scorable cases, the averages (range) for A, U and I scores were:
89% (76-97%), 9% (2-19%) and 2% (1-5%), respectively, showing considerable
variation across the healthcare system. In non-acute patients alone, inappropriate scores
averaged 7% (0-13%) with the following most common reasons: suboptimal use of
medical therapy (96%), low to moderate angina symptoms with low-risk stress tests
(58%), and/or no angina with low to intermediate risk stress tests (40%). Our results
compared favorably to the ACC reports, with approximately 99% concordance.
Conclusion: Our analysis identified several important areas of focus: 1) rates of
suboptimal anti-anginal medical therapy; 2) referrals of low risk patients with low level
angina for revascularization; and 3) the role of stress testing in the revascularization
decision-making process.
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Background: In patients with severe, multivessel coronary disease, coronary artery
bypass grafting (CABG) has been considered the standard of care over percutaneous
coronary intervention (PCI). We will present 4 year outcomes in the 3VD subgroup of
patients in SYNTAX.
Methods: SYNTAX is a randomized clinical trial with parallel nested registries. A
cardiac surgeon and interventional cardiologist screened consecutive pts with de novo
3VD and/or LM disease. Randomization occurred if the patient was amenable to
equivalent revascularization using either treatment. Analysis of the 3VD patient cohort
was prespecified.
Results: : In the 3VD subgroup at 3 years, MACCE was significantly higher in PCI
compared with CABG patients. The rates of death/stroke/MI, death, MI and repeat
revascularization were increased in PCI pts; however, stroke was similar between
groups at 3 years (Table). Partitioning 3VD subgroup patients by SYNTAX Score
tercile demonstrated similar MACCE in patients with low scores (0-22: CABG 22.2%
vs PCI 25.8%, P=0.45); whereas MACCE was increased in patients with intermediate
scores (23-32: 16.8% vs 29.4%, P=0.003). Both MACCE and mortality were increased
in PCI patients with scores ≥33 (17.9% vs 31.4%, P=0.004 and 4.5% vs 11.1%,
P=0.03). Four-year outcomes will be available at the time of the presentation.
Conclusion: At 3 years, MACCE was significantly increased in PCI 3VD compared
with CABG-treated patients; In patients with less complex disease (low SYNTAX
Scores), PCI may be an acceptable revascularization option.
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Background: SYNTAX randomized patients with multivessel and/or left main disease
to PCI and CABG. Patients deemed ineligible for randomization by the heart team
were included in registries. Analysis of these patients is important to understand “real
world” strengths and limitations of PCI and CABG.
Methods: 4337 patients were screened in SYNTAX; 198 and 1077 patients were
included in respectively the PCI and CABG registries. All PCI registry patients and
649 randomly selected CABG registry patients were followed for major adverse cardiac
or cerebrovascular events (MACCE). Patients entered in the PCI registry were
considered inoperable, and in the CABG registry as non-treatable by PCI.
Results: Main reason for inclusion in the CABG registry was excessively complex
coronary anatomy unsuitable for PCI (70.9%). Major co-morbidities were main reasons
for PCI treatment (70.7%). PCI registry patients had a higher risk profile than
randomized patients (EuroSCORE 7.8 ± 9.0 vs 3.8 ± 2.6) but similar lesion complexity
(SYNTAX Score 31.6 ± 12.3 vs 28.4 ± 11.5). Three-year MACCE was 38.0% after
PCI. CABG registry patients had similar EuroSCORE as randomized patients (4.0 ±
4.0 vs 3.8 ± 2.7) but higher SYNTAX Score (37.8 ± 13.3 vs 29.1 ± 11.4). Post-CABG
MACCE at three years was 16.4%. Table 1 lists individual MACCE components.
Stratification in low, intermediate, and high SYNTAX Score demonstrated a stepwise
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